Zheng Tiantian, Lin Fan, Li Xianglin, Chu Tongpeng, Gao Jing, Zhang Shijie, Li Ziyin, Gu Yajia, Wang Simin, Zhao Feng, Ma Heng, Xie Haizhu, Xu Cong, Zhang Haicheng, Mao Ning
School of Medical Imaging, Binzhou Medical University, No. 346 Guanhai Road, Yantai, Shandong, 264003, China.
Department of Radiology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, 264000, China.
EClinicalMedicine. 2023 Mar 17;58:101913. doi: 10.1016/j.eclinm.2023.101913. eCollection 2023 Apr.
Breast cancer is the leading cause of cancer-related deaths in women. However, accurate diagnosis of breast cancer using medical images heavily relies on the experience of radiologists. This study aimed to develop an artificial intelligence model that diagnosed single-mass breast lesions on contrast-enhanced mammography (CEM) for assisting the diagnostic workflow.
A total of 1912 women with single-mass breast lesions on CEM images before biopsy or surgery were included from June 2017 to October 2022 at three centres in China. Samples were divided into training and validation sets, internal testing set, pooled external testing set, and prospective testing set. A fully automated pipeline system (FAPS) using RefineNet and the Xception + Pyramid pooling module (PPM) was developed to perform the segmentation and classification of breast lesions. The performances of six radiologists and adjustments in Breast Imaging Reporting and Data System (BI-RADS) category 4 under the FAPS-assisted strategy were explored in pooled external and prospective testing sets. The segmentation performance was assessed using the Dice similarity coefficient (DSC), and the classification was assessed using heatmaps, area under the receiver operating characteristic curve (AUC), sensitivity, and specificity. The radiologists' reading time was recorded for comparison with the FAPS. This trial is registered with China Clinical Trial Registration Centre (ChiCTR2200063444).
The FAPS-based segmentation task achieved DSCs of 0.888 ± 0.101, 0.820 ± 0.148 and 0.837 ± 0.132 in the internal, pooled external and prospective testing sets, respectively. For the classification task, the FAPS achieved AUCs of 0.947 (95% confidence interval [CI]: 0.916-0.978), 0.940 (95% [CI]: 0.894-0.987) and 0.891 (95% [CI]: 0.816-0.945). It outperformed radiologists in terms of classification efficiency based on single lesions (6 s vs 3 min). Moreover, the FAPS-assisted strategy improved the performance of radiologists. BI-RADS category 4 in 12.4% and 13.3% of patients was adjusted in two testing sets with the assistance of FAPS, which may play an important guiding role in the selection of clinical management strategies.
The FAPS based on CEM demonstrated the potential for the segmentation and classification of breast lesions, and had good generalisation ability and clinical applicability.
This study was supported by the Taishan Scholar Foundation of Shandong Province of China (tsqn202211378), National Natural Science Foundation of China (82001775), Natural Science Foundation of Shandong Province of China (ZR2021MH120), and Special Fund for Breast Disease Research of Shandong Medical Association (YXH2021ZX055).
乳腺癌是女性癌症相关死亡的主要原因。然而,利用医学影像对乳腺癌进行准确诊断在很大程度上依赖于放射科医生的经验。本研究旨在开发一种人工智能模型,用于在对比增强乳腺钼靶摄影(CEM)上诊断单灶性乳腺病变,以辅助诊断流程。
2017年6月至2022年10月期间,在中国三个中心纳入了1912例在活检或手术前有CEM图像上单灶性乳腺病变的女性。样本被分为训练集和验证集、内部测试集、汇总外部测试集和前瞻性测试集。开发了一种使用RefineNet和Xception + 金字塔池化模块(PPM)的全自动管道系统(FAPS),以进行乳腺病变的分割和分类。在汇总外部测试集和前瞻性测试集中,探讨了6名放射科医生的表现以及在FAPS辅助策略下乳腺影像报告和数据系统(BI-RADS)4类的调整情况。使用Dice相似系数(DSC)评估分割性能,使用热图、受试者操作特征曲线下面积(AUC)、敏感性和特异性评估分类性能。记录放射科医生的阅片时间以与FAPS进行比较。本试验已在中国临床试验注册中心注册(ChiCTR2200063444)。
基于FAPS的分割任务在内部测试集、汇总外部测试集和前瞻性测试集中分别实现了0.888±0.101、0.820±0.148和0.837±0.132的DSC。对于分类任务,FAPS实现的AUC分别为0.947(95%置信区间[CI]:0.916 - 0.978)、0.940(95%[CI]:0.894 - 0.987)和0.891(95%[CI]:0.816 - 0.945)。在基于单个病变的分类效率方面,它优于放射科医生(6秒对3分钟)。此外,FAPS辅助策略提高了放射科医生的表现。在两个测试集中,分别有12.4%和13.3%的患者的BI-RADS 4类在FAPS的帮助下得到了调整,这可能在临床管理策略的选择中发挥重要的指导作用。
基于CEM的FAPS展示了乳腺病变分割和分类的潜力,具有良好的泛化能力和临床适用性。
本研究得到了中国山东省泰山学者基金(tsqn202211378)、国家自然科学基金(82001775)、中国山东省自然科学基金(ZR2021MH120)以及山东省医学会乳腺病研究专项基金(YXH2021ZX055)的支持。